Introduction of a self-certification process for labeling updates, allowing for quicker implementation of certain changes to labels and Patient Information Leaflets, unless those changes fall under categories P1-P4 which require a full assessment.
This regulatory update can reduce the time for Marketing Authorisation Holders (MAHs) to implement safety-related changes, thus enhancing patient safety and compliance.
MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.
Regulatory Intelligence Lead
Annual review recommended for compliance updates.
Provides additional procedural details and requirements for using the self-certification route for labelling and PIL updates, ensuring faster implementation of administrative and certain safety-related changes.
MAHs can utilize this streamlined process for specific types of labelling updates, potentially reducing the time required to implement safety-related changes in the PIL and on packaging.
MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.
The new supplementary guidance from the MHRA outlines a self-certification process for submitting changes to labels and Patient Information Leaflets (PILs). This process is designed to enable faster implementation of administrative and specific safety-related changes, provided those changes do not fall into categories requiring full assessment.
What changed: Introduction of a self-certification process for labeling updates, allowing for quicker implementation of certain changes to labels and Patient Information Leaflets, unless those changes fall under categories P1-P4 which require a full assessment.
Why it matters: This regulatory update can reduce the time for Marketing Authorisation Holders (MAHs) to implement safety-related changes, thus enhancing patient safety and compliance.
Practical implication: MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
